Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bpn14770
1. Bpn14770
2. Zatolmilast
3. 1606974-33-7
4. Bpn-14770
5. Zatolmilast [usan]
6. Chembl4541964
7. G786v328x6
8. (4-{[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl}phenyl)acetic Acid
9. 2-[4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl]phenyl]acetic Acid
10. Benzeneacetic Acid, 4-((2-(3-chlorophenyl)-6-(trifluoromethyl)-4-pyridinyl)methyl)-
11. 2-(4-{[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl}phenyl)acetic Acid
12. Zatolmilast [inn]
13. Schembl15660260
14. Unii-g786v328x6
15. Gtpl10451
16. Ex-a5653
17. Bdbm50524994
18. S6844
19. Who 11495
20. Compound 28 [pmid: 31013090]
21. Hy-117571
22. Cs-0066529
23. Kr7
| Molecular Weight | 405.8 g/mol |
|---|---|
| Molecular Formula | C21H15ClF3NO2 |
| XLogP3 | 5.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Exact Mass | 405.0743409 g/mol |
| Monoisotopic Mass | 405.0743409 g/mol |
| Topological Polar Surface Area | 50.2 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 522 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Phosphodiesterase 4 Inhibitors
Compounds that specifically inhibit PHOSPHODIESTERASE 4. (See all compounds classified as Phosphodiesterase 4 Inhibitors.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Zatolmilast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zatolmilast, including repackagers and relabelers. The FDA regulates Zatolmilast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zatolmilast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Zatolmilast supplier is an individual or a company that provides Zatolmilast active pharmaceutical ingredient (API) or Zatolmilast finished formulations upon request. The Zatolmilast suppliers may include Zatolmilast API manufacturers, exporters, distributors and traders.
Zatolmilast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zatolmilast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zatolmilast GMP manufacturer or Zatolmilast GMP API supplier for your needs.
A Zatolmilast CoA (Certificate of Analysis) is a formal document that attests to Zatolmilast's compliance with Zatolmilast specifications and serves as a tool for batch-level quality control.
Zatolmilast CoA mostly includes findings from lab analyses of a specific batch. For each Zatolmilast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zatolmilast may be tested according to a variety of international standards, such as European Pharmacopoeia (Zatolmilast EP), Zatolmilast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zatolmilast USP).
LOOKING FOR A SUPPLIER?
